Non-Hodgkin’s lymphoma (NHL), a cancer affecting the lymphatic system, is the second-fastest-rising cancer in the United States. Incidence rates have nearly doubled over the past 30 years. It is estimated that 360,000 Americans are currently living with NHL, and about 58,000 new cases are expected to occur in the United States this year.
NHL is difficult to target and treat, as the disease can be found throughout the body in any blood-filtering tissue such as bone marrow. Patients typically have multiple relapses, meaning the cancer returns multiple times. This makes it very important for patients, their caretakers and their loved ones to talk to a physician about all available treatment options and to get access to the latest therapies.
NHL patients are traditionally treated with chemotherapy and/or radiation therapy. While these treatments destroy cancer cells, they also destroy surrounding healthy cells. Additionally, chemotherapy and radiation therapy can take up to five months to complete and may require patients to stay in the hospital.
An innovative class of drugs is harnessing the immune system to fight NHL. Radioimmunotherapy (RIT) is a...